Effectiveness of Early Antiretroviral Therapy Initiation to Improve
                    Survival among HIV-Infected Adults with Tuberculosis: A Retrospective Cohort
                    Study by Franke, Molly F. et al.
Effectiveness of Early Antiretroviral Therapy Initiation to
Improve Survival among HIV-Infected Adults with
Tuberculosis: A Retrospective Cohort Study
Molly F. Franke
1,2*, James M. Robins
1,3, Jules Mugabo
4, Felix Kaigamba
5, Lauren E. Cain
1, Julia G.
Fleming
2, Megan B. Murray
1,6
1Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America, 2Partners In Health, Boston, Massachusetts, United
States of America, 3Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America, 4Center for Treatment and Research
on AIDS, Malaria, Tuberculosis and Other Epidemics (TRAC Plus), Rwanda Ministry of Health, Kigali, Rwanda, 5Ruhengeri Hospital, Rwanda Ministry of Health, Ruhengeri,
Rwanda, 6Division of Global Health Equity, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Abstract
Background: Randomized clinical trials examining the optimal time to initiate combination antiretroviral therapy (cART) in
HIV-infected adults with sputum smear-positive tuberculosis (TB) disease have demonstrated improved survival among
those who initiate cART earlier during TB treatment. Since these trials incorporated rigorous diagnostic criteria, it is unclear
whether these results are generalizable to the vast majority of HIV-infected patients with TB, for whom standard diagnostic
tools are unavailable. We aimed to examine whether early cART initiation improved survival among HIV-infected adults who
were diagnosed with TB in a clinical setting.
Methods and Findings: We retrospectively reviewed charts for 308 HIV-infected adults in Rwanda with a CD4 count#350
cells/ml and a TB diagnosis. We estimated the effect of cART on survival using marginal structural models and simulated 2-y
survival curves for the cohort under different cART strategies:start cART 15, 30, 60, or 180 d after TB treatment or never start
cART. We conducted secondary analyses with composite endpoints of (1) death, default, or lost to follow-up and (2) death,
hospitalization, or serious opportunistic infection. Early cART initiation led to a survival benefit that was most marked for
individuals with low CD4 counts. For individuals with CD4 counts of 50 or 100 cells/ml, cART initiation at day 15 yielded 2-y
survival probabilities of 0.82 (95% confidence interval: [0.76, 0.89]) and 0.86 (95% confidence interval: [0.80, 0.92]),
respectively. These were significantly higher than the probabilities computed under later start times. Results were similar for
the endpoint of death, hospitalization, or serious opportunistic infection. cART initiation at day 15 versus later times was
protective against death, default, or loss to follow-up, regardless of CD4 count. As with any observational study, the validity
of these findings assumes that biases from residual confounding by unmeasured factors and from model misspecification
are small.
Conclusions: Early cART reduced mortality among individuals with low CD4 counts and improved retention in care,
regardless of CD4 count.
Please see later in the article for the Editors’ Summary.
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Until recently, there was a paucity of high-quality scientific
evidence regarding the optimal time to initiate combination
antiretroviral therapy (cART) in adults with HIV and tuberculosis
(TB) disease. This uncertainty has posed a major challenge for
clinicians, who often defer cART in individuals initiating TB
treatment because of concern about immune reconstitution
inflammatory syndrome (IRIS) [1–5], the possibility of drug
interactions [6] and adverse side effects [7], and the risk of reduced
adherence due to a higher pill burden among individuals receiving
concomitant treatment. Deferral of cART is not without risk:
higher mortality was observed among HIV-infected TB patients
who received cART either late in the course of TB treatment or
not at all [8–12]. In recognition of this clinical dilemma, a 2005
World Health Organization (WHO) expert panel identified the
assessment of the optimal time to initiate cART as the top research
priority related to antiretroviral therapy (ART) for people living
with HIV and TB [13].
At least four randomized control trials (RCTs) were initiated to
determine whether early versus deferred cART improves survival
among TB patients [14]. RCTs are often regarded as the gold
standard in clinical research because the intervention is randomly
allocated and the potential for confounding by unmeasured factors
is minimized [15]. Randomization is especially useful for
interventions that are preferentially distributed to the sickest
individuals in clinical settings; however, RCTs may be a limited
study choice for providing guidance on the timing of cART
initiation in co-infected patients. First, RCTs require substantial
time and financial resources: to date, only one RCT addressing
this clinical research question has published results, though two
others have reported results in abstract form. Consistent with
observational studies, the SAPiT trial in South Africa found higher
mortality among individuals who started cART after, versus
during, TB treatment [16]. Data from the CAMELIA trial
(presented at the 2010 International AIDS Conference) and the
SAPiT and STRIDE trials (presented at the 2011 Conference on
Retroviruses and Opportunistic Infections) show that, among
adults with severe immune suppression, cART initiation 2–4 wk
after TB treatment improved survival or AIDS-free survival
relative to initiation 8–12 wk after TB treatment [17–19]. Thus,
the first RCT data to provide guidance on this topic did not
become available for a full five years after the WHO expert panel
identified this question as a key research priority.
A second limitation of RCTs for the study of the optimal time
for cART initiation is that they measure the efficacy of an
intervention under controlled conditions that are often difficult to
replicate in clinical settings. For example, three of the RCTs on
cART timing, including the SAPiT and CAMELIA trials,
required smear or culture confirmation of Mycobacterium tuberculosis
[14,16]. Since culture is not available to most of the world’s TB
patients, and HIV-infected patients are often smear-negative, these
inclusion criteria apply to only a minority of co-infected patients at
clinical sites, as few as 20%–35% in some settings [20]. Such
stringent inclusion criteria limit the generalizability of study
findings and may result in discrepancies between the efficacy
observed in RCTs and the actual effectiveness observed in a
clinical setting.
We used routinely collected clinical data from Rwanda, which
can be collected efficiently and inexpensively, to evaluate the
effectiveness of early cART initiation among eligible HIV-infected
adults treated for TB. We utilized appropriate statistical methods
to account for potential biases resulting from the observational
nature of the data. Our aim was to confirm results from
randomized trials among a cohort of HIV-infected adults who
were diagnosed with TB under routine programmatic conditions,
rather than by sputum smear or culture. We also explored whether
early cART initiation reduced the risk of other adverse outcomes,
including default and loss to follow-up.
Methods
Ethics Statement
This study was approved by the Partners Human Research
Committee and the Rwanda National Ethics Committee.
Study Setting and Population
We conducted this study among HIV-infected cART-eligible
adults$15 y who had not previously initiated lifelong cART and
who received a first TB treatment at one of five cART sites (two
urban, three rural) in Rwanda between January 2004 and
February 2007. The five health facilities were government-run
sites that were receiving financial support from the Global Fund to
Fight AIDS, Tuberculosis, and Malaria, and additional financial
and implementation support from a non-governmental organiza-
tion (Partners In Health or Me ´decins Sans Frontie `res). Both
ambulatory patients and individuals who were interned at the
clinic or an on-site hospital were eligible for inclusion. Physicians
initiated cART according to the Rwanda Ministry of Health
eligibility criteria during the study period (WHO HIV disease
stage 4 regardless of CD4 cell count, WHO HIV disease stage 2 or
3 with a CD4 cell count , 350; WHO HIV disease stage 1 with a
CD4 cell count , 200) [21]. Because TB disease corresponds to
WHO HIV disease stage 3, for this analysis, we considered an
individual to be cART eligible if s/he had a documented CD4 cell
count#350 cells/ml prior to, or during, TB treatment. TB
regimens were directly observed and consisted of rifampin,
isoniazid, pyrazinamide and ethambutol. cART was directly
observed at least once per day for individuals who received
treatment at the rural sites and was self-administered by
individuals treated at the urban sites. The first-line cART regimen
for HIV-infected individuals on TB treatment consisted of
stavudine or zidovudine, lamivudine and efavirenz. Nevirapine
replaced efavirenz in individuals who were not receiving TB
treatment. Cotrimoxazole was routinely prescribed to individuals
with CD4 cell count , 350 cells/ml or WHO HIV disease stage 2,
3, or 4. CD4 cell counts were conducted prior to cART initiation
and every 6 mo thereafter [21].
Data Collection and Study Design
We conducted a retrospective review of each patient’s TB and
HIV charts and other program records to collect baseline
demographic and clinical variables as well as relevant clinical
follow-up data. Follow-up for each person began on the TB
treatment initiation date or the date of the first CD4 cell
count#350 cells/ml, whichever came later. Because a CD4 cell
count#350 cells/ml was required for study inclusion and was not
documented for some individuals until after TB treatment
initiation, we excluded person-time corresponding to the period
between TB treatment initiation and first CD4 cell count#350
cells/ml (a total of 7,130 person-days) because this was ‘‘immortal
person-time,’’ e.g., person-time that precedes completion of study
entry criteria [15]. Patients had the potential to be followed for at
least 1 y and a maximum of 2 y after TB treatment initiation.
Exposure and Outcome Definitions
Because the therapeutic effect of cART is gradual [22], and
deaths immediately following cART initiation are likely due to
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individual was considered to be ‘‘on cART.’’ We assessed death as
the primary outcome, and individuals who defaulted (e.g., stopped
treatment without clinician approval), were lost to follow-up, or
were followed for less than 2 y were censored on their last day of
follow-up. We conducted secondary analyses with composite
endpoints of (1) death, default, or lost to follow-up; and (2) death,
hospitalization due to any cause, or any of the following WHO
HIV disease stage 3 or 4 opportunistic infections: cryptococcal
meningitis, esophageal candidiasis, HIV encephalopathy, Kaposi’s
sarcoma, lymphoma, pneumonia/pneumopathy, or recurrent TB.
For this endpoint, we included hospitalizations that began at least
1 wk after TB treatment initiation to avoid those that coincided
with the initial TB diagnosis. Individuals were considered lost to
follow-up 2 mo after their last visit if they (1) were reported by a
clinician to have defaulted or been lost to follow-up, (2) were not
documented to have received HIV care after completion of TB
treatment, or (3) had no visit notes or laboratory results within 4
mo of the 2-y follow-up period or date of chart review, whichever
came first. This third criterion was used to account for the fact that
losses to follow-up may go unnoticed by clinicians if the patient
does not subsequently return to the center.
Statistical Analyses
We first estimated the mortality hazard ratios of ‘‘on cART’’
and time ‘‘on cART,’’ using a marginal structural Cox
proportional hazards model. To do this, we fit a logistic regression
model pooled over time and subject with death at day t as the
outcome and time-varying variables for ‘‘on cART’’ at day t, and
number of days ‘‘on cART’’ at day t. The following baseline
covariates were also included in the model: the value of the first
CD4 cell count#350 cells/ml (henceforth, first CD4 cell count)
(linear), an interaction term between first CD4 cell count and ‘‘on
cART,’’ age$43 y (75
th percentile), gender, site (rural versus
urban), in-patient at a health facility at TB treatment initiation
(versus out-patient), lack of a CD4 cell count at the time of TB
treatment initiation, time between TB start and first CD4 cell
count (if positive), and follow-up day. We also considered the
location and type of TB and baseline weight in the lowest gender-
specific quartile as potential confounding baseline variables for the
effect of ‘‘on cART,’’ but since these variables did not change the
effect estimate for ‘‘on cART’’ by more than 10% and did not
predict mortality at p , 0.05, we excluded them from the final
model. We used inverse probability weighting to adjust for time-
varying confounding by CD4 cell count and in-patient health
facility status and to account for the possibility that sicker
individuals may have been more likely to have shorter follow-up
for reasons other than death (e.g., losses to follow-up) [23,24].
Further details are described in Text S1.
For all analyses, the most recent CD4 cell count was carried
forward until a new result was received, and follow-up day was
modeled as a flexible cubic spline with knots at 60, 180, and 360.
Although we tested the variable representing time ‘‘on cART’’ for
linearity using a stepwise spline regression model with knots at the
same locations [25], the spline term was not selected for the final
model at a p , 0.05, and we therefore used the continuous linear
form. We did not find evidence of statistically significant
interaction between ‘‘on cART’’ and any other baseline covariates
or follow-up time, nor of a third-order interaction between ‘‘on
cART,’’ follow-up time, and time between TB treatment initiation
and first CD4 cell count.
In the second set of analyses we compared the causal effect of
different cART start times on survival by using the weighted
estimates from the final multivariable model to estimate survival
probabilities for each individual, based on his/her baseline
characteristics. We set the ‘‘on cART’’ and time ‘‘on cART’’
variables to estimate the 2-y mean survival probability that would
be expected if everyone in the cohort initiated cART a given
number of days after TB treatment. Because TB treatment start
may be a more relevant reference time point than time since first
CD4 cell count, we set the variables for ‘‘missing a CD4 cell count
at the time of TB treatment initiation’’ and ‘‘time between TB
start and first CD4 cell count’’ to zero, in order to estimate the
Table 1. Descriptive data for study cohort.
Category Variable
Binary
Variables,
Number (%)
Continuous
Variables,
Median
(Range)
Patient
characteristics
Age (years) 37 (18–77)
Female gender 187 (60.7)
Location and
type of TB
disease
(n= 280)
a
Pulmonary,
smear positive
47 (16.8)
Pulmonary,
smear negative
71 (25.4)
Pulmonary,
smear not done
72 (25.7)
Extra-pulmonary,
total
b
90 (32.1)
Extra-pulmonary,
disseminated
28 (38.4)
Extra-pulmonary,
ganglion
26 (35.6)
Extra-pulmonary,
abdominal
11 (15.1)
Extra-pulmonary,
pleural
7 (9.6)
Extra-pulmonary,
meningitits
3 (4.1)
Extra-pulmonary,
pericardial
1 (1.4)
CD4 cell count CD4 cell count#350
cells/ml, available
at TB start
192 (62.3)
If CD4 count not
available at TB start,
days to first CD4#350
cells/ml( n= 116)
45 (2–209)
First CD4 cell
count#350 cells/ml
113 (1–350)
cART initiation Never started cART 46 (14.9)
Time to cART
start (days) (n= 262)
72.5 (0–716)
In-patient status In-patient at health
facility at TB start
98 (31.8)
Outcome Died 49 (15.9)
Time to death (days)
(n= 49)
70 (1–669)
Lost to follow-up or
defaulted
32 (10.4)
n =308, unless otherwise noted.
aTwenty-eight individuals lacked data on location/type of TB.
bData on the location of extra-pulmonary TB was available for 73 individuals.
doi:10.1371/journal.pmed.1001029.t001
Effectiveness of Early cART
PLoS Medicine | www.plosmedicine.org 3 May 2011 | Volume 8 | Issue 5 | e1001029causal effect of cART among individuals who have a CD4 cell
count at the time of TB treatment initiation. We plotted survival
probabilities for five cART initiation strategies:start cART 15 d,
30 d, 60 d, or 180 d after TB treatment start, or never start
cART. Because we incorporated a 15-d lag for the ‘‘on cART’’
variable, individuals were assumed to not have experienced any
effect of cART until 15 d after cART initiation. For example, for
the treatment strategy ‘‘start cART 15 d after TB treatment start,’’
the effect of cART was applied 15 d after cART initiation (30 d
after TB treatment start). Standard errors and 95% confidence
intervals (CIs) for the simulated survival curves were calculated
using a nonparametric unconditional bootstrap [26] (n= 500
bootstrap samples). We tested differences in 2-y survival
probabilities by dividing those differences by the standard error
of the difference in 2-y survival probabilities from the bootstrap
samples (type 1 error probability =0.05 using the usual normal
quantiles as cutoff for the statistic).
Results
Primary Outcome
Table 1 shows baseline characteristics for the 308 individuals
included in the study cohort. Thirty-seven of the 49 deaths during
follow-up (75.5%) occurred in the first 6 mo after TB treatment
initiation. Time-varying risk factors for cART initiation and
censoring are reported in Tables S1 and S2. We found a
statistically significant protective effect of cART on mortality,
which was greatest among individuals with lower first CD4 cell
counts (Table 2; Wald test for interaction, p =0.03). Figure 1
displays survival probabilities for each of the cART treatment
strategies, with first CD4 cell count values set to 50, 100, 200, and
300 cells/ml. When we set first CD4 cell counts to 50 and 100
cells/ml, starting cART at day 15 resulted in mean survival
probabilities at 2 y of 0.82 (95% CI: [0.76, 0.89]) and 0.86 (95%
CI: [0.80, 0.92]), which were statistically significantly higher than
the survival probabilities resulting from each of the other
treatment strategies (Figure 1; Table S3). We did not detect
statistically significant differences in survival probabilities when we
set first CD4 cell counts to 200 or 300 cells/ml, in
spite of a tendency toward higher survival probabilities for cART
initiation times#60 d compared to 180 d and never (Table S3).
Results were similar when we considered lags of 7 and 21 d before
an individual was considered to be ‘‘on cART’’ (results not shown)
and when we treated age as a continuous variable.
Secondary Outcomes
The relationship between early cART and the composite
endpoint of death, hospitalization, or serious opportunistic infection
was similar to that observed for the outcome of death. Initiation of
cART 15 d after TB treatment for individuals with CD4 cell counts
of 50 or 100 cells/ml yielded a higher probability of remaining free
of death, hospitalization, or serious opportunistic infection at 2 y
than later initiation of cART (Figure 2; Table S3). We did not
observe statistically significant differences in these 2-y probabilities
when we set CD4 cell counts to 200 or 300 cells/ml. Compared to
later times, cART initiation 15 d after TB treatment was strongly
protective against death, default, or loss to follow-up (Figure 3;
Table S4), and this effect did not differ by first CD4 cell count.
Deaths in the First 15 d following cART Initiation
Of the 29 individuals who died after initiation of cART, 11
(37.9%) did so within 15 d of cART initiation. This group
demonstrated advanced HIV disease (median CD4 cell count: 54
cells/ml) and initiated cART a median of 53 d after TB treatment
(range:8–131 d).
Discussion
We conclude that cART initiation after 15 d of TB treatment is
more beneficial on an absolute scale (measured by differences in
survival probabilities) among individuals with TB who have CD4
cell counts#100 cells/ml, compared with later initiation. Early
Table 2. Multivariable model for the effect of cART and baseline covariates on study outcomes.
Variable
Death (165,164
Person-Days, 49 Events)
Death, Default, Lost to
Follow-Up (165,164 Person-
Days, 81 Events)
Death, Hospitalization, Serious
Opportunistic Infection (140,687
Person-Days, 102 Events)
Hazard Ratio
[95% CI] p-Value
Hazard Ratio
[95% CI] p-Value
Hazard Ratio
[95% CI] p-Value
‘‘On cART’’ 0.3 [0.1, 1.1] 0.06 0.3 [0.1, 0.6] 0.0005 0.4 [0.2, 0.8] 0.02
Weeks ‘‘on cART’’
a 1.0 [0.9, 1.0] 0.005 1.0 [0.9, 1.0] 0.009 1.0 [0.9, 1.0] 0.10
First CD4 cell count (per 20-cell increase, linear) 0.8 [0.7, 0.9] 0.002 0.9 [0.9, 1.0] 0.003 0.9 [0.8, 1.0] ,0.001
Interaction between ‘‘on cART’’ and
value of first CD4 cell count#350 cells/ml
1.2 [1.0, 1.4] 0.03
—b 1.1 [1.0, 1.2] 0.03
Missing a CD4 cell count at TB treatment start 0.6 [0.3, 1.4] 0.25 1.2 [0.6, 2.2] 0.62 0.9 [0.5, 1.6] 0.65
Weeks between TB treatment start and first
CD4 cell count#350 cells/ml, if positive
a
1.0 [1.0, 1.1] 0.55 1.0 [1.0, 1.1] 0.57 1.0 [0.9, 1.0] 0.48
Age$43 y (75
th percentile) 1.7 [0.9, 3.4] 0.12 1.1 [0.6, 2.0] 0.69 1.5 [0.9, 2.4] 0.10
Female gender 1.6 [0.8, 3.2] 0.20 1.1 [0.6, 1.8] 0.84 1.3 [0.8, 2.0] 0.32
Rural treatment site 1.4 [0. 7, 3.0] 0.36 0.9 [0.5, 1.6] 0.71 0.8 [0.4, 1.3] 0.32
In-patient at health facility at TB start 2.1 [1.1, 4.3] 0.04 1.4 [0.9, 2.5] 0.17 1.8 [1.1, 2.8] 0.02
Estimates are adjusted for all other variables in model and follow-up day, most recent CD4 cell count, and current hospitalization.
aDays ‘‘on cART’’ and days to first CD4 cell count#350 cells/ml transformed to the week scale.
bThe interaction between ‘‘on cART’’ and value of first CD4 cell count#350 cells/ml was not statistically significant for the combined endpoint of death, default, and lost
to follow-up and was therefore not included in this multivariable model.
doi:10.1371/journal.pmed.1001029.t002
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risks, for individuals with CD4 cell counts$200 cells/ml: the
difference in survival probabilities was smaller when CD4 cell
counts were set to 200 and 300 cells/ml, and we may have lacked
statistical power to detect small differences. Given that individuals
with CD4 cell counts$200 cells/ml are eligible for cART in most
HIV programs, the higher survival probabilities observed for
individuals with a CD4 cell count of 200 cells/ml who initiated
cART by day 60, although not statistically significant, suggest that
there is no reason to defer cART past 60 d in this group. Early
cART may also increase retention in care for all individuals with
CD4 cell counts#350 cells/ml.
Unlike participants in most RCTs, individuals included in this
study were diagnosed with TB by a clinician, but were not
required to demonstrate sputum that was smear- or culture-
positive for M. tuberculosis. Because only a small percentage of TB
cases in HIV-infected individuals are diagnosed by sputum smear
or culture, our results provide evidence of the effectiveness of early
cART initiation as it is implemented in most clinical settings in
areas with high burdens of HIV and TB. The concept of
effectiveness is distinct from, yet complementary to, the efficacy of
early cART reported from RCTs [14,16], which may not be
generalizable to the majority of individuals who are treated for TB
in the absence of smear or culture confirmation.
The CAMELIA trial was conducted among a group of HIV-
infected adults with advanced disease (median CD4 cell count: 25
cells/ml). The authors reported 100-wk survival probabilities of
0.82 (95% CI: [0.78, 0.86]) and 0.73 (95% CI: [0.68, 0.78])
among individuals who initiated cART 2 and 8 wk after TB
treatment initiation, respectively [17]. These 2-y survival
probabilities are remarkably similar to those we computed for
individuals with a first CD4 cell count of 50 cells/ml who initiated
treatment 15 d and 60 d after TB treatment initiation: 0.82 (95%
CI: [0.76, 0.89]) and 0.76 (95% CI: [0.68, 0.83]), respectively.
Our results are also consistent with the SAPiT and STRIDE
results, which found that cART initiation after 2–4 wk improved
survival or AIDS-free survival compared to initiation at 8–12 wk
only among individuals with severe immune suppression (i.e.,
CD4 cell counts#50 cells/ml) [18,19]. Taken together, we
conclude that the RCT results may be generalized to the
majority of HIV-infected TB patients. These findings also
support the notion that observational data, when combined with
appropriate analytic methods, should be considered as an ethical,
inexpensive, and time-efficient strategy to address urgent clinical
questions when RCT results are pending.
Multiple factors contribute to a clinician’s ability to initiate
cART promptly. Timely HIV diagnosis and referral to HIV
services and CD4 cell count enumeration are required for early
Figure 1. Survival curves for ‘‘when to start’’ strategies, stratified by first CD4 cell count, endpoint of death. (A) Mean probability of
survival when first CD4 cell count was set to 50 cells/ml (A), 100 cells/ml (B), 200 cells/ml (C), or 300 cells/ml (D).
doi:10.1371/journal.pmed.1001029.g001
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and testing services, integrated TB and HIV care, and systems that
ensure that patients return promptly for appointments will likely
facilitate early cART initiation and further reduce mortality
among HIV-infected individuals with TB. Early cART was
protective against the composite endpoint of death, default, or
lost to follow-up, which suggests that TB treatment might offer a
brief and valuable window of opportunity for referral and linkage
to HIV services, particularly for individuals who have less
advanced HIV disease.
Through the use of a marginal structural model we simulated a
randomized trial of five cART treatment strategies (start cART
15, 30, 60, or 180 d after TB treatment initiation or never start).
Of course, using marginal structural models to simulate an RCT
with our data does not have the guarantees of a true RCT.
Rather the validity of our study findings depend on several
assumptions. First, we assume that the baseline and time-varying
confounders for which we adjusted fully account for differences
between those who do and do not initiate cART (and were or
were not censored). Second, we assume that the model we used to
calculate the survival probability for each day of follow-up is
correctly specified and predicts survival accurately. Multiple
studies have found cART or CD4 cell count to be the strongest
determinants of survival among individuals with TB and HIV
[8,27–29]; both of these variables were included in our model.
For parsimony, we chose to include only statistically significant
interactions between ‘‘on cART’’ and the other variables in our
model; however, the relatively small size of this cohort and small
number of outcomes may have limited our ability to detect and
model important interactions between cART and other variables.
We incorporated a lag of 15 d before an individual was
considered to be ‘‘on cART,’’ since deaths occurring before this
time are likely due to advanced HIV disease. If some of the
deaths occurring within the first 15 d of cART had been due to
cART (e.g., TB IRIS or toxicity), the incorporation of this lag
would overestimate the benefit of cART. However, median time
between cART initiation and TB IRIS onset or diagnosis ranges
from 11 to 46 d [6,30], and deaths from TB IRIS and toxicity
appear to be rare [2,30–32], suggesting that such bias would be
minimal.
The health centersincluded in this study weregovernment health
facilities that were also supported by non-governmental organiza-
tions that provided additional resources and support to the facility
and to patients. These additional resources may have led to an
Figure 2. Survival curves for ‘‘when to start’’ strategies, stratified by first CD4 cell count, endpoint of death, serious opportunistic
infection, or hospitalization. Mean probability of survival without incident of serious opportunistic infection or hospitalization when first CD4 cell
count was set to 50 cells/ml (A), 100 cells/ml (B), 200 cells/ml (C), 300 cells/ml (D).
doi:10.1371/journal.pmed.1001029.g002
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relative to centers without these resources. The study was also
conducted during a period of HIV treatment scale-up and program
strengthening, which continued in the years following the study
period. The absolute survival probabilities reported here may be
higher than those at centers without non-governmental support,
and may have increased in the years since the study period.
However, for these factors to limit the generalizability of our finding
that earlier cART initiation improves survival relative to later
initiation, the effect of cART initiation among cART-eligible
patients with TB would need to differ according to the level of
health centers’ resources or overall quality of care.
In conclusion, we recommend cART initiation after 15 d of TB
treatment for those with CD4 cell counts#100 cells/ml and by day
60 for individuals with CD4 cell counts of 101–200 cells/ml, and
advocate for TB treatment to be used as an opportunity to refer
and retain HIV-infected individuals in care, regardless of CD4 cell
count. We also support prioritization of financial and human
resources to maximize the quality and utilization of observational
data, which are plentiful in TB and HIV programs throughout the
world and may be informative for examining the effectiveness of
different treatment strategies. Although the biases associated with
use of these data must be carefully addressed, failure to draw upon
the experiences of national treatment programs may come at a
formidable cost to clinicians, patients, and their families as they
await results from RCTs.
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Background. HIV infection has exacerbated the global
tuberculosis (TB) epidemic, especially in sub-Saharan Africa,
in which in some countries, 70% of people with TB are
currently also HIV positive—a condition commonly
described as HIV/TB co-infection. The management of
patients with HIV/TB co-infection is a major public health
concern.
There is relatively little good evidence on the best time to
initiate combination antiretroviral therapy (cART) in adults
with HIV/TB co-infection. Clinicians sometimes defer cART in
individuals initiating TB treatment because of concerns
about complications (such as immune reconstitution inflam-
matory syndrome) and the risk of reduced adherence if
patients have to remember to take two sets of pills.
However, starting cART later in those patients who are
infected with both HIV and TB can result in potentially
avoidable deaths during therapy.
Why Was This Study Done? Several randomized control
trials (RCTs) have been carried out, and the results of three of
these studies suggest that, among individuals with severe
immune suppression, early initiation of cART (two to four
weeks after the start of TB treatment) leads to better survival
than later ART initiation (two to three months after the start
of TB treatment). These results were reported in abstract
form, but the full papers have not yet been published. One
problem with RCTs is that they are carried out under
controlled conditions that might not represent well the
conditions in varied settings around the world. Therefore,
observational studies that examine how effective a
treatment is in routine clinical conditions can provide
information that complements that obtained during clinical
trials. In this study, the researchers aimed to confirm the
results from RCTs among a cohort of adult patients with HIV/
TB co-infection in Rwanda, diagnosed under routine
program conditions and using routinely collected clinical
data. The researchers also wanted to investigate whether
early cART initiation reduced the risk of other adverse
outcomes, including treatment default and loss to follow-up.
What Did the Researchers Do and Find? The researchers
retrospectively reviewed the charts and other program
records of 308 patients with HIV, who had CD4
counts#350 cells/ml, were aged 15 years or more, had
never previously taken cART, and received their first TB
treatment at one of five cART sites (two urban, three rural) in
Rwanda between January 2004 and February 2007. Using
this method, the researchers collected baseline demographic
and clinical variables and relevant clinical follow-up data.
They then used this data to estimate the effect of cART on
survival by using sophisticated statistical models that
calculated the effects of initiating cART at 15, 30, 60, or
180 d after the start of TB treatment or not at all.
The researchers then conducted a further analysis to assess
combined outcomes of (1) death, default, lost to follow-up,
and (2) death, hospitalization due to any cause, or
occurrence of severe opportunistic infections, such as
Kaposi’s sarcoma. The researchers used the resulting
multivariable model to estimate survival probabilities for
each individual, based on his/her baseline characteristics.
The researchers found that when they set their model to first
CD4 cell counts of 50 and 100 cells/ml, and starting cART at
day 15, mean survival probabilities at two years were 0.82
and 0.86, respectively, statistically significantly higher than
the survival probabilities calculated for each of the other
treatment strategies, where cART was started later. They
observed a similar pattern for the combined outcome of
death, hospitalization, or serious opportunistic infection In
addition, two-year outcomes for death or lost to follow-up
were also improved with early cART, regardless of CD4 count
at treatment initiation.
What Do These Findings Mean? These findings show
that in a real world program setting, starting cART 15 d after
the start of TB treatment is more beneficial (measured by
differences in survival probabilities) among patients with
HIV/TB co-infection who have CD4 cell counts#100 cells/ml
than starting later. Early cART initiation may also increase
retention in care for all individuals with CD4 cell counts#350
cells/ml.
As the outcomes of this modeling study are based on data
from a retrospective observational study, the biases associ-
ated with use of these data must be carefully addressed.
However, the results support the recommendation of cART
initiation after 15 d of TB treatment for patients with CD4 cell
counts#100 cells/ml and can be used as an advocacy base for
TB treatment to be used as an opportunity to refer and retain
HIV-infected individuals in care, regardless of CD4 cell count.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001029.
N Information is available on HIV/TB co-infection from the
World Health Organization , the US Centers for Disease
Control and Prevention, and the International AIDS Society
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